SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.36-2.8%3:28 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (13426)10/8/2004 1:47:42 PM
From: Biomaven  Read Replies (2) of 52153
 
I wonder whether the fallout from the Vioxx debacle isn't going to be fairly prolonged. It might cause some investors to question the whole risk/reward characteristics of pharma, and by extension biotech. Certainly to the extent the FDA becomes more cautious that hurts pharma and biotech, in the short run at least.

The Chiron vaccine problems also don't help. And if Lilly loses the Zyprexa patent case then confidence could be really shaken.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News